BIOMAT Database Logo BIOMAT Database Logo

Platelet dysfunction during cardiopulmonary bypass surgery. With special reference to platelet membrane glycoproteins. 1993

C Kondo, and K Tanaka, and K Takagi, and T Shimono, and H Shinpo, and I Yada, and H Yuasa, and M Kusagawa, and N Akamatsu, and K Tanoue
Department of Thoracic Surgery, Mie University School of Medicine, Japan.

Changes in platelet membrane glycoproteins (GPIb, GPIIb/IIIa, and GMP-140) were evaluated using flow cytometry after binding with monoclonal antibodies in 22 adult patients undergoing cardiopulmonary bypass (CPB) surgery. The amount of GPIb on platelets decreased significantly during CPB, reaching a minimum level of 64 +/- 26% of the pre CPB value at 120 min of CPB. There was no significant change in the amount of GPIIb/IIIa on platelets. In accordance with these changes, ristocetin induced agglutination decreased to 56.7 +/- 16.2% of the pre CPB value during CPB. However, there were no significant changes in ADP and collagen induced aggregation throughout the procedure. The number of the activated platelets expressing GMP-140 on their surfaces increased significantly during CPB. There was an upper limit to the amount of GMP-140 expression on each platelet in the circulating blood, suggesting that excessively activated platelets are removed from the circulation. The authors conclude that CPB reduces the amount of GPIb on platelets, which results in platelet dysfunction. In addition, removal of excessively activated platelets from the circulation may lead to thrombocytopenia after CPB.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010107 Oxygenators, Membrane Devices in which blood and oxygen are separated by a semipermeable membrane, generally of Teflon or polypropylene, across which gas exchange occurs. The membrane may be arranged as a series of parallel plates or as a number of hollow fibers; in the latter arrangement, the blood may flow inside the fibers, which are surrounded by gas, or the blood may flow outside the fibers and the gas inside the fibers. (Dorland, 28th ed) Membrane Oxygenator,Membrane Oxygenators,Oxygenator, Membrane
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D010980 Platelet Membrane Glycoproteins Surface glycoproteins on platelets which have a key role in hemostasis and thrombosis such as platelet adhesion and aggregation. Many of these are receptors. PM-GP,Platelet Glycoprotein,Platelet Membrane Glycoprotein,PM-GPs,Platelet Glycoproteins,Glycoprotein, Platelet,Glycoprotein, Platelet Membrane,Glycoproteins, Platelet,Glycoproteins, Platelet Membrane,Membrane Glycoprotein, Platelet,Membrane Glycoproteins, Platelet,PM GP
D002315 Cardiopulmonary Bypass Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs. Heart-Lung Bypass,Bypass, Cardiopulmonary,Bypass, Heart-Lung,Bypasses, Cardiopulmonary,Bypasses, Heart-Lung,Cardiopulmonary Bypasses,Heart Lung Bypass,Heart-Lung Bypasses
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D005260 Female Females
D006349 Heart Valve Diseases Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE). Heart Valvular Disease,Valvular Heart Diseases,Disease, Heart Valvular,Heart Disease, Valvular,Heart Valve Disease,Heart Valvular Diseases,Valve Disease, Heart,Valvular Disease, Heart,Valvular Heart Disease
D006350 Heart Valve Prosthesis A device that substitutes for a heart valve. It may be composed of biological material (BIOPROSTHESIS) and/or synthetic material. Prosthesis, Heart Valve,Cardiac Valve Prosthesis,Cardiac Valve Prostheses,Heart Valve Prostheses,Prostheses, Cardiac Valve,Prostheses, Heart Valve,Prosthesis, Cardiac Valve,Valve Prostheses, Cardiac,Valve Prostheses, Heart,Valve Prosthesis, Cardiac,Valve Prosthesis, Heart

Related Publications

C Kondo, and K Tanaka, and K Takagi, and T Shimono, and H Shinpo, and I Yada, and H Yuasa, and M Kusagawa, and N Akamatsu, and K Tanoue
Platelet dysfunction associated with cardiopulmonary bypass.
April 1978, The Annals of thoracic surgery,
C Kondo, and K Tanaka, and K Takagi, and T Shimono, and H Shinpo, and I Yada, and H Yuasa, and M Kusagawa, and N Akamatsu, and K Tanoue
Heparin, cardiopulmonary bypass, and platelet dysfunction.
June 2006, Artificial organs,
C Kondo, and K Tanaka, and K Takagi, and T Shimono, and H Shinpo, and I Yada, and H Yuasa, and M Kusagawa, and N Akamatsu, and K Tanoue
Complement activation in cardiopulmonary bypass, with special reference to anaphylatoxin production in membrane and bubble oxygenators.
July 1988, The Annals of thoracic surgery,
C Kondo, and K Tanaka, and K Takagi, and T Shimono, and H Shinpo, and I Yada, and H Yuasa, and M Kusagawa, and N Akamatsu, and K Tanoue
Autoantibody production after cardiopulmonary bypass with special reference to postpericardiotomy syndrome.
November 1992, The Journal of pediatrics,
C Kondo, and K Tanaka, and K Takagi, and T Shimono, and H Shinpo, and I Yada, and H Yuasa, and M Kusagawa, and N Akamatsu, and K Tanoue
[Platelet consumption and its prevention during cardiopulmonary bypass with a membrane oxygenator].
September 1986, [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai,
C Kondo, and K Tanaka, and K Takagi, and T Shimono, and H Shinpo, and I Yada, and H Yuasa, and M Kusagawa, and N Akamatsu, and K Tanoue
Platelet dysfunction, platelet function tests and cardiopulmonary bypass with heparin anticoagulation.
July 2002, Thrombosis research,
C Kondo, and K Tanaka, and K Takagi, and T Shimono, and H Shinpo, and I Yada, and H Yuasa, and M Kusagawa, and N Akamatsu, and K Tanoue
Platelet studies during cardiopulmonary bypass.
September 1999, The Annals of thoracic surgery,
C Kondo, and K Tanaka, and K Takagi, and T Shimono, and H Shinpo, and I Yada, and H Yuasa, and M Kusagawa, and N Akamatsu, and K Tanoue
Heparin-induced platelet dysfunction and cardiopulmonary bypass.
June 2000, The Annals of thoracic surgery,
C Kondo, and K Tanaka, and K Takagi, and T Shimono, and H Shinpo, and I Yada, and H Yuasa, and M Kusagawa, and N Akamatsu, and K Tanoue
Platelet preservation during cardiopulmonary bypass with aprotinin.
January 1989, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
C Kondo, and K Tanaka, and K Takagi, and T Shimono, and H Shinpo, and I Yada, and H Yuasa, and M Kusagawa, and N Akamatsu, and K Tanoue
Penicillin-induced dysfunction of platelet membrane glycoproteins.
April 1993, The Journal of laboratory and clinical medicine,
Copied contents to your clipboard!